|
|
 | | | |
- close
- close
- close
- close
INHX » Topics » If we are successful in pursuing other preclinical and clinical antiviral development opportunities through in-licensing, acquisition or merger, your ownership in us could be diluted.This excerpt taken from the INHX 10-Q filed Aug 9, 2007. If we
are successful in pursuing other preclinical and clinical
antiviral development opportunities through in-licensing,
acquisition or merger, your ownership in us could be
diluted.
We anticipate that we will need to issue additional shares of
common stock in the future to support or fund our current
strategy and our planned operations. Any issuance of equity we
may undertake in the future could cause the price of our common
stock to decline, or require us to issue shares at a price that
is lower than that paid by holders of our common stock in the
past, which would result in those shares being dilutive. If we
obtain funds through a credit facility or through the issuance
of debt or preferred securities, these securities would likely
have rights senior to your rights as a common stockholder.
|
| |||||||
